Author | Lightnews

Arndt Vogel

Arndt Vogel

@arndtvogel.bsky.social

370 followers 220 following 46 posts

Clinician-Scientist, ESMO Ambassador, focussed on Liver Cancer & Precision Oncology, Toronto General Hospital/Princess Margaret Cancer Center 🇨🇦/MHH🇩🇪

Posts Media Videos Starter Packs

Arndt Vogel @arndtvogel.bsky.social · Mar 27

🔥off the press
Health-related quality of life in participants with advanced biliary tract cancer from the phase III KEYNOTE-966 study
@JHepatology doi.org/10.1016/j.jh...
👉Health-related quality of life maintained after adding pembrolizumab to GemCis
@myESMO @EASLedu @ILCAnews @curecc

Arndt Vogel @arndtvogel.bsky.social · Mar 26

🔥off the press
Liposomal irinotecan for previously treated pts with BTC: A pooled analysis of NIFTY & NALIRICC
@JHepatology
🔎🇩🇪&🇰🇷 co-production
👉sig. ORR & PFS benefit
👉trend for OS
🤔Is there a role for Irino in BTC?
😅decide for yourself...
@myESMO @EASLedu @ILCAnews @cure

Arndt Vogel @arndtvogel.bsky.social · Mar 4

🔥Nivolumab and Ipilimuma approved by EMA for advanced hepatocellular carcinoma 🔥
👇https://ec.europa.eu/health/documents/community-register/html/h1014.htm
👉great news for our patients > more options in 1st line
😅amazing: approval in 🇪🇺by EMA before 🇺🇸by FDA
@myESMO @EASLedu @ILCAnews #livertwitter

Arndt Vogel @arndtvogel.bsky.social · Feb 22

🔥off the press
Precision surgery for hepatocellular carcinoma
@LancetGastroHep
doi.org/10.1016/S246...
👉the field is moving to precision medicine
👉Our thoughts on current strategies & future opportunities > team work is key for personalized therapy
@myESMO

Arndt Vogel @arndtvogel.bsky.social · Feb 21

A phase III randomised study of first-line NUC-1031/ cisplatin vs GemCis in advanced biliary tract cancer
@JHepatology
doi.org/10.1016/j.jh...
👉mOS 9.2 vs 12.6 mo
👉Early toxicity & liver injury in exp. arm
😨Not only 🚫, but even detrimental
@myESMO @EASLedu @ILCAnews

Arndt Vogel @arndtvogel.bsky.social · Feb 21

🔥off the press
Recent advances in systemic therapy for advanced biliary tractcancer: A systematic review & meta-analysis usingreconstructed RCT survival data
@JHEP_Reports
👇now online available
doi.org/10.1016/j.jh...
👉very modest progress
🧐we need biomarker & better 💊
@myESMO @EASLedu

Arndt Vogel @arndtvogel.bsky.social · Feb 21

Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
@CCR_AACR
doi.org/10.1158/1078...
👉not all MSI tumors respond to ICI
👉NGS & RNA seq can help to identify responders
@myESMO

Arndt Vogel @arndtvogel.bsky.social · Feb 21

Neoadjuvant mFOLFOX With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer
@Annals_Oncology
doi.org/10.1200/JCO-...
🔎10-yr Follow-Up of FOWARC trial
🧐neoadjuvant mFOLFOX6 is a therapeutic option in LARC

Arndt Vogel @arndtvogel.bsky.social · Feb 21

🔥off the press
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
@LancetRH_Europe
doi.org/10.1016/j.la...
👉there are striking disparities in access to innovative💊& molecular testing
🧐we urgently need a more harmonised path forward

Arndt Vogel @arndtvogel.bsky.social · Feb 20

Tremelimumab & durvalumab as neoadjuvant or non-operative management strategy for MSI GC/GEJ cancer
@Annals_Oncology
doi.org/10.1016/j.an...
🔎 INFINITY study by GONO
👉17 pts > 13 cCR > non-operative management > only 1 recurrence
🧐W&W in GC/GEC ... exciting
@myESMO

Arndt Vogel @arndtvogel.bsky.social · Feb 20

Pembrolizumab versus chemotherapy in MSI colorectal cancer
@Annals_Oncology
doi.org/10.1016/j.an...
🔎5-yr follow wo KEYNOTE-177
👉mPFS 16.5 vs 8.2 mo
👉mOS 77.5 vs 36.7 mo (37% cross over)
👉5-year OS rate: 54.8s% v 44.2%
🧐we need biomarker .. Nivo/Ipi vs pembro
@myESMO

Arndt Vogel @arndtvogel.bsky.social · Feb 20

Clinicogenomic landscape of #PDAC identifies KRAS mutant dosage as prognostic of overall survival
@NatureMedicine
doi.org/10.1038/s415...
👉Very comprehensive analysis on the impact of KRAS
👉Key for understanding de novo and acquired resistance to RAS 💊
@myESMO

Arndt Vogel @arndtvogel.bsky.social · Feb 20

🔥off the press:
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
@Annals_Oncology
doi.org/10.1016/j.an...
👉get the lastest update on HCC management
👉Multiple options > MDT is key
@myESMO @EASLedu @ILCAnews #livertwitter

Arndt Vogel @arndtvogel.bsky.social · Feb 12

Advances in liquid biopsy: From exploration to practical application
@Cancer_Cell
doi.org/10.1016/j.cc...
👏Excellent review on liquid biopsy
👉LP will be key for disease monitoring and to understand resistence mechanisms
@myESMO

Arndt Vogel @arndtvogel.bsky.social · Feb 12

Liver metastases do not predict resistance to the addition of atezolizumab to FOLFOXIRI + bevacizumab in proficient MMR mCRC
@ESMO_Open
doi.org/10.1016/j.es...
🔎 Post-hoc AtezoTRIBE study
👉LM prognostic, not predictive
🧐Do we need to rethink LM & ICI efficacy in mCRC?
@myESMO

Arndt Vogel @arndtvogel.bsky.social · Feb 12

Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy
@JNCI_Now
doi.org/10.1093/jnci...
🔎🇺🇸RWD, >200pts
👉HAI with CTx can offer long-term durable disease control: mOS >20mo
@myESMO @EASLedu @ILCAnews #livertwitter

Arndt Vogel @arndtvogel.bsky.social · Feb 12

🔥hot off the press
@ESMO_Open
doi.org/10.1016/j.es...
ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma
👉get the latest update on management
@myESMO

Arndt Vogel @arndtvogel.bsky.social · Feb 7

Atezolizumab Plus CTx With or Without Bevacizumab in BTC
🔎 Clinical & Biomarker Data From Phs II IMbrave151 Trial
@JCO_ASCO
👉ORR 26 vs 26%
👉mPFS 8.3 vs 7.9 mo
👉mOS 14.9 vs 14.6 mo
👉High VEGFA may be a predictive biomarker
🧐❌trail, not sure whether to proceed...

Arndt Vogel @arndtvogel.bsky.social · Feb 7

Trial of Gemcitabine, Cisplatin & Nab-Paclitaxel vs Gemcitabine/ Cisplatin in BTC
@JCO_ASCO
doi.org/10.1200/JCO-...
🔎SWOG S1815 phs III
👉ORR 31 vs 21 %
👉mPFS 7.5 vs 6.3 mo
👉mOS 14 vs 13.6 mo
🧐🚫 trial, maybe an option subgroups such locally advanced or gallbladder

Arndt Vogel @arndtvogel.bsky.social · Feb 7

Mismatch repair andMSI phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence & prognostic impact
European Journal of Cancer
doi.org/10.1016/j.ej...
🔎🗺️RWD, 23.893 pts
👉MMR-m status not associated with MSI in 48.9 % of cases
🧐need of comprehensive testing

Arndt Vogel @arndtvogel.bsky.social · Feb 6

Baseline Liquid Biopsy in Relation to Tissue-Based
Parameters in mCRC
@JCO_ASCO

doi.org/10.1200/JCO....
🔎FIRE-4 (AIO-KRK-0114) Study
👉LB allows detection of RAS/ BRAF must in pt deemed RASwt on basis of tissue > behave like RAS/BRAF muts...
🧐Better to know..supports LB...…

Arndt Vogel @arndtvogel.bsky.social · Feb 6

Combined Analyses of ctDNA &Immunoscore in Stage III Colon Cancer
🔎Post Hoc of PRODIGE-GERCOR IDEA-France/
HORG-IDEA-Greece Trials
@JCO_ASCO
doi.org/10.1200/JCO....
👉ctDNA in 19.7% of pts > independent prognostic 🖍️
👉IS additional prognostic info in 80%
🧐Time for implantation in clinical practice..

Arndt Vogel @arndtvogel.bsky.social · Feb 6

fficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
@NEJM

doi.org/10.1056/NEJM...
🔎Ph2-2, 204 pts, 12 tumor types
👉 bispecific antibody against HER2 & HER3,
👉ORR 30%, DoR 11.1 mo, mPFS 6.8 mo
👉ORR 40% in #PDAC, 20% in BTC
🧐Effective..
@myESMO @EASLedu @ILCAnews

Arndt Vogel @arndtvogel.bsky.social · Feb 5

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced GC/GEJ cancer
@lancet oncology
doi.org/10.1016/ S1470-2045(24)00636-3
🔎 KYM901 phs 1 trial
👉ORR 29%, DCR 68%
👉SAE ≥3 68%
👉first CLDN18.2- specific ADC
🧐Phs 3 ongoing...

Arndt Vogel @arndtvogel.bsky.social · Feb 5

Thermal ablation versus surgical resection of small-size colorectal liver metastases
@TheLancetOncol
doi.org/10.1016/S147...
🔎COLLISION phs 3 non-inferiority trial, 300 pts
👉 stopped early
👉SAE 7 vs 20%
👉Similar OS and local control
🧐Both are effective treatment options